StockData
Onconetix, Inc. logo

Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$0.43−0.05 (-10.13%)

Close on Oct 19, 2026Market cap $965.06KP/E –Yield –

Onconetix free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Onconetix's free cash flow for the twelve months ending Dec 31, 2024 was -$10.52M. For fiscal 2024 it was -$10.52M.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$10.52M–
FY2023Dec 31, 2023-$13.58M–
FY2022Dec 31, 2022-$8.68M–
FY2021Dec 31, 2021-$2.05M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$921.52K–
Q3 FY2024Sep 30, 2024-$1.15M–
Q2 FY2024Jun 30, 2024-$3.22M–
Q1 FY2024Mar 31, 2024-$5.24M–
Q4 FY2023Dec 31, 2023-$4.31M–
Q3 FY2023Sep 30, 2023-$3.04M–
Q4 FY2022Dec 31, 2022-$2.80M–
Q3 FY2022Sep 30, 2022-$1.81M–
Q2 FY2022Jun 30, 2022-$3.18M–
Q1 FY2022Mar 31, 2022-$891.29K–

More Onconetix figures

See a number that looks wrong?